Morphological and Functional Evaluation of Irvine-Gass Syndrome
NCT ID: NCT01504074
Last Updated: 2015-09-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: 30 patients suffering on Cystoid macular edema (CME) secondary to Cataract surgery will be observed and evaluated by fluorescein-angiography, SD-OCT, reading performance, contrast sensitivity and microperimetry in a fixed time schedule
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Radial Peripapillary Vessel Density in Irvine-gass Syndrome
NCT06436170
"Cataract Surgery in Eyes With Epiretinal Membrane"
NCT03404323
Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green.
NCT00376857
Cystoid Macular Edema After Vitrectomy for Rhegmatogenous Retinal Detachment
NCT05069675
The Role of Intravitreal Glucose in Macular Thinning Following Surgery for Retinal Detachment or Epimacular Membrane
NCT02210481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients suffering on CME secondary to cataract surgery
if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection
if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection
if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* St.p Cataract surgery
* able to read
* informed consent
* with fluorescein angiography and SD-OCT diagnosed Irvine Gass syndrome
Exclusion Criteria
* CME of other origin
* diabetic macular edema
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marion Munk
MD, Principal Investigator, Department of Ophthalmology and Optometry,
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Ophthalmology Medical University of Vienna
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
071/2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.